Tumortherapie synchroner Malignome verschiedener Organe – ein Fall für die interdisziplinäre Onkologie

Schlüsselwörter

Interdisziplinarität - Medikamentöse Tumortherapie - simultan - EML-ALK - Induktionstherapie - interdisciplinarity - medical oncology - synchronous - EML-ALK - induction chemotherapy

Publication History

Received: 24 May 2021

Accepted after revision: 28 June 2021

Article published online:
23 July 2021

• Literatur

• 1 Jiao F, Yao L, Zhou J. et al. Clinical features of multiple primary malignancies: a retrospective analysis of 72 Chinese patients. Asian Pac. J. Cancer Prev 2014; 15: 331-334
• 2 Bagri P. et al. Double primary malignancies: a clinical & pathological analysis report from a regional cancer institute in India. Iran. J. cancer Prev 2014; 7: 66-72
• 3 Donin N. et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016; 122 (19) 3075-3086
• 4 Luttke M, Späth R, Marschner S. et al. Induktionschemotherapie mit Cisplatin und Gemcitabin, gefolgt von Radiochemotherapie bei Nasopharynxkarzinomen Induction Chemotherapy with Gemcitabine and Cisplatin followed by Radiochemotherapy in locally advanced Nasopharyngeal Carcinoma. Strahlentherapie und Onkol 2020; 196 (08) 740-742
• 5 Zhang Y. et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med 2019; 381: 1124-1135
• 6 Wong D. et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115: 1723-1733
• 7 Soda M, Choi Y, Enomoto M. et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566
• 8 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Larynxkarzinoms, Kurzversion 1.1 – Januar 2019, AWMF-Registernummer: 017 – 076OL.